Literature DB >> 18690032

Mutational analysis of block and facilitation of HERG current by a class III anti-arrhythmic agent, nifekalant.

Yukio Hosaka1, Miki Iwata, Narutoshi Kamiya, Mitsuhiko Yamada, Kengo Kinoshita, Yoshifumi Fukunishi, Kenji Tsujimae, Hiroshi Hibino, Yoshifusa Aizawa, Atsushi Inanobe, Haruki Nakamura, Yoshihisa Kurachi.   

Abstract

Chemicals and toxins are useful tools to elucidate the structure-function relationship of various proteins including ion channels. The HERG channel is blocked by many compounds and this may cause life-threatening cardiac arrhythmia. Besides block, some chemicals such as the class III anti-arrhythmic agent nifekalant stimulate HERG at low potentials by shifting its activation curve towards hyperpolarizing voltages. This is called "facilitation". Here, we report mutations and simulations analyzing the association between nifekalant and channel pore residues for block and facilitation. Alanine-scanning mutagenesis was performed in the pore region of HERG. The mutations at the base of the pore helix (T623A), the selectivity filter (V625A) and the S6 helix (G648A, Y652A and F656A) abolished and S624A attenuated both block and facilitation induced by the drug. On the other hand, the mutation of other residues caused either an increase or a decrease in nifekalant-induced facilitation without affecting block. An open-state homology model of the HERG pore suggested that T623, S624, Y652 and F656 faced the central cavity, and were positioned within geometrical range for the drug to be able to interact with all of them at the same time. Of these, S649 was the only polar residue located within possible interaction distance from the drug held in its blocking position. Further mutations and flexible-docking simulations suggest that the size, but not the polarity, of the side chain at S649 is critical for drug induced facilitation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18690032     DOI: 10.4161/chan.4691

Source DB:  PubMed          Journal:  Channels (Austin)        ISSN: 1933-6950            Impact factor:   2.581


  8 in total

Review 1.  Revealing the structural basis of action of hERG potassium channel activators and blockers.

Authors:  Matthew Perry; Michael Sanguinetti; John Mitcheson
Journal:  J Physiol       Date:  2010-07-19       Impact factor: 5.182

2.  A small molecule screening to detect potential therapeutic targets in human podocytes.

Authors:  Eugen Widmeier; Weizhen Tan; Merlin Airik; Friedhelm Hildebrandt
Journal:  Am J Physiol Renal Physiol       Date:  2016-10-19

3.  Structure-Based Prediction of hERG-Related Cardiotoxicity: A Benchmark Study.

Authors:  Teresa Maria Creanza; Pietro Delre; Nicola Ancona; Giovanni Lentini; Michele Saviano; Giuseppe Felice Mangiatordi
Journal:  J Chem Inf Model       Date:  2021-09-10       Impact factor: 6.162

4.  The amiodarone derivative KB130015 activates hERG1 potassium channels via a novel mechanism.

Authors:  Guido Gessner; Regina Macianskiene; John G Starkus; Roland Schönherr; Stefan H Heinemann
Journal:  Eur J Pharmacol       Date:  2010-01-25       Impact factor: 4.432

Review 5.  Minimizing repolarization-related proarrhythmic risk in drug development and clinical practice.

Authors:  Attila S Farkas; Stanley Nattel
Journal:  Drugs       Date:  2010-03-26       Impact factor: 9.546

6.  The molecular determinants of R-roscovitine block of hERG channels.

Authors:  Bryan Cernuda; Christopher Thomas Fernandes; Salma Mohamed Allam; Matthew Orzillo; Gabrielle Suppa; Zuleen Chia Chang; Demosthenes Athanasopoulos; Zafir Buraei
Journal:  PLoS One       Date:  2019-09-03       Impact factor: 3.240

7.  Facilitation of I Kr current by some hERG channel blockers suppresses early afterdepolarizations.

Authors:  Kazuharu Furutani; Kunichika Tsumoto; I-Shan Chen; Kenichiro Handa; Yuko Yamakawa; Jon T Sack; Yoshihisa Kurachi
Journal:  J Gen Physiol       Date:  2019-01-23       Impact factor: 4.086

8.  The Prostacyclin Analogue, Treprostinil, Used in the Treatment of Pulmonary Arterial Hypertension, is a Potent Antagonist of TREK-1 and TREK-2 Potassium Channels.

Authors:  Kevin P Cunningham; Lucie H Clapp; Alistair Mathie; Emma L Veale
Journal:  Front Pharmacol       Date:  2021-06-29       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.